End-of-day quote
Shanghai S.E.
06:00:00 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
24.69
CNY
|
+1.11%
|
|
+7.82%
|
-40.43%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
25,488
|
20,876
|
16,580
|
9,853
|
-
|
-
|
Enterprise Value (EV)
1 |
25,488
|
20,876
|
16,580
|
9,853
|
9,853
|
9,853
|
P/E ratio
|
35
x
|
38.4
x
|
148
x
|
39.8
x
|
30.1
x
|
25.2
x
|
Yield
|
-
|
0.79%
|
0.29%
|
0.49%
|
1.01%
|
1.17%
|
Capitalization / Revenue
|
11.8
x
|
11.3
x
|
12.9
x
|
6.56
x
|
5.54
x
|
4.79
x
|
EV / Revenue
|
11.8
x
|
11.3
x
|
12.9
x
|
6.56
x
|
5.54
x
|
4.79
x
|
EV / EBITDA
|
29,645,138
x
|
28,328,876
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
62.1
x
|
211
x
|
43.8
x
|
28.3
x
|
18.7
x
|
FCF Yield
|
-
|
1.61%
|
0.47%
|
2.28%
|
3.53%
|
5.35%
|
Price to Book
|
5.61
x
|
4.29
x
|
4.29
x
|
2.43
x
|
2.3
x
|
2.16
x
|
Nbr of stocks (in thousands)
|
400,000
|
400,000
|
400,000
|
399,083
|
-
|
-
|
Reference price
2 |
63.72
|
52.19
|
41.45
|
24.69
|
24.69
|
24.69
|
Announcement Date
|
2/22/22
|
2/27/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
2,154
|
1,848
|
1,284
|
1,502
|
1,779
|
2,055
|
EBITDA
|
-
|
859.8
|
736.9
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
811.5
|
638.6
|
130.9
|
292
|
384
|
456
|
Operating Margin
|
-
|
37.68%
|
34.56%
|
10.2%
|
19.44%
|
21.59%
|
22.19%
|
Earnings before Tax (EBT)
1 |
-
|
809.9
|
638.4
|
131.6
|
292
|
385
|
457
|
Net income
1 |
558.4
|
690.3
|
544.2
|
112.3
|
250
|
328
|
390
|
Net margin
|
-
|
32.05%
|
29.45%
|
8.75%
|
16.64%
|
18.44%
|
18.98%
|
EPS
2 |
1.560
|
1.820
|
1.360
|
0.2800
|
0.6200
|
0.8200
|
0.9800
|
Free Cash Flow
1 |
-
|
-
|
336.2
|
78.55
|
225
|
348
|
527
|
FCF margin
|
-
|
-
|
18.19%
|
6.12%
|
14.98%
|
19.56%
|
25.64%
|
FCF Conversion (EBITDA)
|
-
|
-
|
45.62%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
61.78%
|
69.94%
|
90%
|
106.1%
|
135.13%
|
Dividend per Share
2 |
-
|
-
|
0.4100
|
0.1200
|
0.1200
|
0.2500
|
0.2900
|
Announcement Date
|
4/23/21
|
2/22/22
|
2/27/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
336
|
78.5
|
225
|
348
|
527
|
ROE (net income / shareholders' equity)
|
-
|
20.1%
|
11.7%
|
2.81%
|
6.1%
|
7.6%
|
8.5%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
11.40
|
12.20
|
9.670
|
10.20
|
10.80
|
11.40
|
Cash Flow per Share
|
-
|
1.780
|
1.110
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
107
|
40.9
|
51
|
41
|
33
|
Capex / Sales
|
-
|
-
|
5.81%
|
3.19%
|
3.4%
|
2.3%
|
1.61%
|
Announcement Date
|
4/23/21
|
2/22/22
|
2/27/23
|
2/29/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -40.43% | 1.36B | | +73.17% | 12.38B | | -18.74% | 7.92B | | +16.15% | 7.2B | | +4.81% | 5.84B | | +5.99% | 5.01B | | +27.07% | 4.53B | | -21.67% | 3.88B | | -40.82% | 2.23B | | +1.49% | 2.02B |
Medical Equipment
|